524717 — Titan Biotech Income Statement
0.000.00%
- IN₹3.98bn
- IN₹3.91bn
- IN₹1.64bn
- 92
- 22
- 34
- 48
Annual income statement for Titan Biotech, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | R2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 794 | 1,422 | 1,235 | 1,440 | 1,641 |
Cost of Revenue | |||||
Gross Profit | 401 | 777 | 550 | 606 | 729 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 671 | 986 | 946 | 1,171 | 1,331 |
Operating Profit | 123 | 436 | 289 | 269 | 310 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 104 | 427 | 290 | 281 | 315 |
Provision for Income Taxes | |||||
Net Income After Taxes | 78.4 | 317 | 217 | 210 | 237 |
Minority Interest | |||||
Equity in Affiliates | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 70.7 | 303 | 217 | 248 | 249 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 70.7 | 303 | 217 | 248 | 249 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 8 | 37 | 26.2 | 30.1 | 30.1 |
Dividends per Share |